Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
An update from Lexaria Bioscience ( (LEXX) ) is now available.
Lexaria Bioscience is progressing with its Phase 1b human study in Australia, investigating the safety and efficacy of its DehydraTECH-tirzepatide formulation for diabetes control and weight loss. The study has received ethical approval for all initial study arms, and plans are underway to add a fifth arm based on promising prior results that showed improved blood glucose reduction and fewer adverse events when using DehydraTECH technology. This development marks a significant step in Lexaria’s efforts to shift diabetes treatment from injections to oral delivery systems, potentially enhancing patient experience and compliance.
More about Lexaria Bioscience
Lexaria Bioscience Corp. is a global innovator in drug delivery platforms, focusing on enhancing the efficacy and safety of drug formulations. The company is known for its proprietary DehydraTECH technology, which aims to improve the oral delivery of drugs, particularly in the areas of diabetes control and weight management.
YTD Price Performance: -23.04%
Average Trading Volume: 192,036
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $31.07M
See more insights into LEXX stock on TipRanks’ Stock Analysis page.
